While we are focused on developing the best possible cannabinoid products, we believe that improving the health and wellbeing of patients goes beyond this. That’s why we are committed to investing in research and development.
In addition to continuing to invest in research and development in-house, we understand that a strong partnership with clinicians and researchers is key to expanding the industry and helping people.
By prioritising research, we have the power to discover the full potential of cannabinoid medicines in treating diseases and improving lives. That’s why we partner with key universities to undertake cannabis research and support their clinical trial programs.
The aim of the survey completed by 640 Australian general practitioners (GP) was to examine the knowledge and attitudes of GP towards medicinal cannabis. The results show that the majority of surveyed practitioners are supportive or neutral when it comes to medicinal cannabis use.
This review of 49 studies assesses the use of medicinal cannabis for anxiety-related disorders. The available evidences demonstrates there is a potential benefit of cannabinoids in reducing anxiety behaviors relevant to disorders such as PTSD, GAD, PD, OCD, and SAD, with no anxiogenic effects. The authors emphasise the potential value and need for further study of CBD in the treatment of anxiety disorders.
We currently have a research partnership with the Hunter Medical Research Institute, a partner of the University of Newcastle. For more information about how to become a partner please contact us.